Changes in the volume of residual pituitary adenomas in patients with adult-onset growth hormone deficiency during replacement therapy with the recombinant human growth hormone.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

In the course of a prospective study concerning recombinant human growth hormone replacement therapy in adult-onset growth hormone deficiency, the researchers determined the volumes of residual tumors in six patients with pituitary macroadenomas who had formerly been treated with surgery alone or surgery and external radiotherapy.

Pituitary CT scans in direct coronal views were obtained at baseline, and at 6, 12 and 18 months.

Who Took Part

The abstract describes 38 patients taking part.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized study.

The patients were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

What Was Measured

The subject headings attached to it are Adenoma, Age of Onset, Growth Hormone, Hormone Replacement Therapy, Human Growth Hormone, Neoplasm, Residual and Pituitary Neoplasms.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 38 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1999 (Wiener klinische Wochenschrift), a journal based in Austria.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.